Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary adenomas (PAs) lie between benign adenomas and true malignant PCs and are defined as aggressive-invasive PAs, characterized by a hig...
Guardado en:
Autores principales: | Congxin Dai, Siyu Liang, Bowen Sun, Yong Li, Jun Kang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8fe4900f61c6430098f966006066a7df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Baseline MRI findings as predictors of hypopituitarism in patients with non-functioning pituitary adenomas
por: Reem Al Argan, et al.
Publicado: (2021) -
Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review
por: Odelia Cooper, et al.
Publicado: (2021) -
Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches
por: Changxi Han, et al.
Publicado: (2021) -
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
por: Giuseppe Giuffrida, et al.
Publicado: (2021) -
Comparative evaluation of several parameters of glycemic homeostasis in patients with functional pituitary adenomas
por: Rostislavovna Mikityuk, et al.
Publicado: (2014)